VACC
Closed
Vaccitech Plc Adr
3.52
+0.21 (+6.34%)
Last Update: 26 Dec 2023 17:30:00
Yesterday: 3.31
Day's Range: 3.222 - 3.52
Send
sign up or login to leave a comment!
When Written:
2.37
Vaccitech PLC ADR is a clinical-stage biopharmaceutical company that focuses on developing and commercializing immunotherapeutics and vaccines for infectious diseases and cancer. The company was founded in 2016 and is headquartered in Oxford, United Kingdom.
Vaccitech's proprietary platform technology, known as the Chimpanzee Adenovirus Vector (ChAdOx) platform, is designed to stimulate and enhance the body's immune response to specific antigens. The company's lead product candidate is a COVID-19 vaccine developed in partnership with the University of Oxford, which has been authorized for emergency use in several countries.
Vaccitech is also developing vaccine candidates for other infectious diseases, including MERS, HPV, and tuberculosis, as well as immunotherapies for cancer. The company has collaborations with several pharmaceutical and biotech companies, including AstraZeneca, GSK, and the Bill and Melinda Gates Foundation.
Vaccitech went public in April 2021 through a merger with a special purpose acquisition company (SPAC), resulting in the company being listed on the NASDAQ under the ticker symbol "VACC".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Vaccitech's proprietary platform technology, known as the Chimpanzee Adenovirus Vector (ChAdOx) platform, is designed to stimulate and enhance the body's immune response to specific antigens. The company's lead product candidate is a COVID-19 vaccine developed in partnership with the University of Oxford, which has been authorized for emergency use in several countries.
Vaccitech is also developing vaccine candidates for other infectious diseases, including MERS, HPV, and tuberculosis, as well as immunotherapies for cancer. The company has collaborations with several pharmaceutical and biotech companies, including AstraZeneca, GSK, and the Bill and Melinda Gates Foundation.
Vaccitech went public in April 2021 through a merger with a special purpose acquisition company (SPAC), resulting in the company being listed on the NASDAQ under the ticker symbol "VACC".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!